Reduction of Adverse Drug Events and Readmissions
Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.
| Condition(s) | Pharmacogenomic Testing for Medication Management |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation. |
| Who can participate | INCLUSION CRITERIA Patients may be included in the Study if they meet all of the following inclusion criteria: 1. Male or female patients of 25 years of age or older who are able to give their written Informed Consent to participate in a Clinical Study based on voluntary agreement with a thorough explanation of the patient's participation will be provided to them. 2. Patient underwent PGx testing for alleles appropriate to the target drugs within the prior 120 days ("index PGx test assessment"); 3. Patient was receiving at least one medication known to be associated with allelic variation at the time of the ("index PGx test assessment"), including over-the- counter medications; 4. Patient has a history of at least one TDAE over the 24-month period preceding the PGx test assessment, or has |
| Ages | 25 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | ClinLogic LLC |
| Locations | York, Pennsylvania, United States |
| Start date | 2019-03-15 |
| NCT ID | NCT02738047 |
| Official listing | https://clinicaltrials.gov/study/NCT02738047 |